The treatment “has broad implications for multiple types of cancer,” said lead author Dr. Joshua Brody.
An experimental cancer “vaccine” showed promising results in a small clinical trial of patients with lymphoma, according to a study published Monday in the journal Nature Medicine.
Researchers at New York’s Mount Sinai Hospital tested the treatment in 11 patients with lymphoma. Their results were successful enough to warrant another clinical trial in March on lymphoma patients as well as breast and head-and-neck cancer.
Researchers said some patients in the initial human trial went into full remission for months or even years.
The treatment “has broad implications for multiple types of cancer,” said lead author, Dr. Joshua Brody, director of the lymphoma immunotherapy program. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
|Read on: [wp_colorbox_media url=”https://www.cnbc.com/2019/04/08/cancer-vaccine-shows-promise-in-human-trial-of-lymphoma-patients.html” type=”iframe” hyperlink=”Cancer ‘vaccine’ shows promise in human trial of lymphoma patients”]|